Preimplantation Genetic Diagnosis Market, By Type (Chromosomal Abnormalities, Aneuploidy, X-linked diseases, Single gene disorders, HLA Typing, Gender Selection, Others (for disability, adult onset disease)), By End User (Diagnostic Laboratories, Hospital

Preimplantation Genetic Diagnosis Market, By Type (Chromosomal Abnormalities, Aneuploidy, X-linked diseases, Single gene disorders, HLA Typing, Gender Selection, Others (for disability, adult onset disease)), By End User (Diagnostic Laboratories, Hospitals, Clinics), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Preimplantation genetic diagnosis (PGD) is the genetic profiling of the pre implantable embryos and oocytes before their implantation. The preimplantation genetic diagnosis is similar to that of the parental diagnosis in case of screening for a particular genetic disease. The PGD is advantageous in a way that helps to avoid selective pregnancy termination by the development and growth of the healthy fetus. PGD serves as an addendum to assisted reproductive technology. The preimplantation genetic diagnosis is required in vitro fertilization, in order to obtain oocytes from the embryos for the genetic evaluation of the diseased or disease-free conditions. In simpler terms, the preimplantation genetic diagnosis is a technique that is used to identify embryos at risk.
Restraints of the Global Preimplantation Genetic Diagnosis Market
Major factors hampering the growth of the preimplantation genetic diagnosis market during the forecast period constitutes of non-availability of embryos for transfer.
Key features of the study:
This report provides in-depth analysis of the global preimplantation genetic diagnosis market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021, as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
It profiles leading players in the global preimplantation genetic diagnosis market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include Amgen, Quest Diagnostics, Genentech Inc., Vertex, PerkinElmer, Inc., F. Hoffman-La-Roche Ltd, Thermo Fisher Scientific, Inc., Laboratory Corporation of America Holdings, Abbott Laboratories, Illumina, Inc., Natera Inc., CooperGenomics Inc., Reproductive Genetics Institute, Inc., Genea Ltd., Invitae Corporation, and CombiMatrix Corporation.
Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
The global preimplantation genetic diagnosis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.
Detailed Segmentation
Global Preimplantation Genetic Diagnosis Market, By Type:
Chromosomal Abnormalities
Aneuploidy
X-linked diseases
Single gene disorders
HLA Typing
Gender Selection
Others (for disability, adult onset disease)
Global Preimplantation Genetic Diagnosis Market, By End User:
Diagnostic Laboratories
Hospitals
Clinics
Global Preimplantation Genetic Diagnosis Market, By Geography:
North America
By Type
Chromosomal Abnormalities
Aneuploidy
X-linked diseases
Single gene disorders
HLA Typing
Gender Selection
Others (for disability, adult onset disease)
By End User
Diagnostic Laboratories
Hospitals
Clinics
By Country:
U.S.
Canada
Europe
By Type
Chromosomal Abnormalities
Aneuploidy
X-linked diseases
Single gene disorders
HLA Typing
Gender Selection
Others (for disability, adult onset disease)
By End User
Diagnostic Laboratories
Hospitals
Clinics
By Country:
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
By Type
Chromosomal Abnormalities
Aneuploidy
X-linked diseases
Single gene disorders
HLA Typing
Gender Selection
Others (for disability, adult onset disease)
By End User
Diagnostic Laboratories
Hospitals
Clinics
By Country:
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
By Type
Chromosomal Abnormalities
Aneuploidy
X-linked diseases
Single gene disorders
HLA Typing
Gender Selection
Others (for disability, adult onset disease)
By End User
Diagnostic Laboratories
Hospitals
Clinics
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Middle East:
By Type
Chromosomal Abnormalities
Aneuploidy
X-linked diseases
Single gene disorders
HLA Typing
Gender Selection
Others (for disability, adult onset disease)
By End User
Diagnostic Laboratories
Hospitals
Clinics
By Country:
GCC
Israel
Rest of Middle East
Africa
By Type
Chromosomal Abnormalities
Aneuploidy
X-linked diseases
Single gene disorders
HLA Typing
Gender Selection
Others (for disability, adult onset disease)
By End User
Diagnostic Laboratories
Hospitals
Clinics
By Country/Region:
Central Africa
South Africa
North Africa
Company Profiles
Amgen Inc.*
Company Overview
Product Portfolio
Financial Performance
Key Strategies
Recent Developments
Quest Diagnostics
Vertex
PerkinElmer, Inc.
F. Hoffman-La-Roche Ltd
Thermo Fisher Scientific, Inc.
Laboratory Corporation of America Holdings
Abbott Laboratories
Illumina, Inc.
Natera Inc.
CooperGenomics Inc.
Reproductive Genetics Institute, Inc.
Genea Ltd.
Invitae Corporation
CombiMatrix Corporation
“*” marked represents similar segmentation in other categories in the respective section.